Page 23 - Read Online

de Santis et al. Hepatoma Res 2019;5:1 I http://dx.doi.org/10.20517/2394-5079.2018.65 Page 15 of 16

2018? A review. Dig Liver Dis 2018;50:640-6.
12. Ryu SW, Bok GH, Jang JY, Jeong SW, Ham NS, et al. Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal
liver masses: comparison to computed tomography and magnetic resonance imaging. Gut Liver2014;8:292-7.
13. Dulku G, Dhillon R, Goodwin M, Cheng W, Kontorinis N, et al. The role of imaging in the surveillance and diagnosis of
hepatocellular cancer. J Med Imaging Radiat Oncol 2017;61:171-9.
14. Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.
Eur J Radiol 2018;101:72-81.
15. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma.Hepatology 2005;42:1208-36.
16. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, et al. New MR imaging criteria with a diffusion-weighted sequence for the
diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011;55:126-32.
17. Raman SS, Leary C, Bluemke DA, Amendola M, Sahani D, et al. Improved characterization of focal liver lesions with liver-specific
gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr
2010;34:163-72.
18. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic
acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology
2010;255:824-33.
19. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, et al. Detection and characterization of focal liver lesions: a Japanese phase
III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed
tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010;45:133-41.
20. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic
review and meta-analysis. Hepatology 2018;67:401-21.
21. ACR. Liver reporting and data system. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-
RADS/LI-RADS1. [Last accessed on 20 Dec 2018]
22. ACR. CT/MRI LI-RADS® v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/
CT-MRI-LI-RADS-v2017. [Last accessed on 20 Dec 2018]
23. ACR. Ultrasound LI-RADS® v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/
Ultrasound-LI-RADS-v2017. [Last accessed on 20 Dec 2018]
24. Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular
carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med
2015;36:132-9.
25. ACR. CEUS LI-RADS® v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/
CEUS-LI-RADS-v2017. [Last accessed on 20 Dec 2018]
26. Wilson SR, Lyshchik A, Piscaglia F, Cosgrove D, Jang HJ, et al. CEUS LI-RADS: algorithm, implementation, and key differences
from CT/MRI. Abdom Radiol (NY) 2018;43:127-42.
27. Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma
in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol 2018;68:485-92.
28. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, et al. EASL clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2018;69:182-236.
29. Kojiro M, Wanless IR, Alves V, Badve S, Balabaud C, et al. Pathologic diagnosis of early hepatocellular carcinoma: a report of the
international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
30. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, et al. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than
3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 2009;193:W482-9.
31. Park YS, Lee CH, Kim JW, Shin S, Park CM. Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic
resonance imaging: what are the tips when using hepatocyte-specific agents? World J Gastroenterol 2016;22:284-99.
32. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, et al. The uptake transporter OATP8 expression decreases during multistep
hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-66.
33. Sirlin CB, Kielar AZ, Tang A, Bashir MR. LI-RADS: a glimpse into the future. Abdom Radiol (NY) 2018;43:231-6.
34. Park JW, Kim JH, Kim SK, Kang KW, Park KW, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of
primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912-21.
35. Park JH, Kim DH, Kim SH, Kim MY, Baik SK, et al. The clinical implications of liver resection margin size in patients with
hepatocellular carcinoma in terms of positron emission tomography positivity. World J Surg 2018;42:1514-22.
36. Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, et al. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular
carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 2012;18:53-61.
37. Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, et al. Clinical usefulness of (18) F-fluorodeoxyglucose positron emission
tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular
carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatol Res 2013;43:481-7.
38. Yoh T, Seo S, Ogiso S, Kawai T, Okuda Y, et al. Proposal of a new preoperative prognostic model for solitary hepatocellular carcinoma
incorporating 18F-FDG-PET imaging with the ALBI grade. Ann Surg Oncol 2018;25:542-9.
39. Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, et al. Evaluating treatment response of radioembolization in intermediate-
stage hepatocellular carcinoma patients using 18F-fluoroethylcholine PET/CT. J Nucl Med 2015;56:1661-6.
40. Di Martino M, Saba L, Bosco S, Rossi M, Miles KA, et al. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical,
radiological and pathological findings. Eur Radiol 2014;24:1446-54.